Bimagrumab

Bimagrumab is being studied in combination with GLP-1 agonists (e.g., semaglutide) and dual GLP-1/GIP agonists for synergistic fat loss while preserving lean muscle mass. The combination approach leverages bimagrumab's muscle-protective mechanism alongside the metabolic and appetite-suppressing effects of incretin-based therapies. No specific dosing protocols are mentioned in the transcript.

In the BELIEVE clinical trial, participants treated with a combination of bimagrumab and semaglutide achieved more than 20% total body weight loss. Notably, 92% of that weight loss was attributed to fat mass, suggesting strong muscle-sparing or muscle-preserving effects from bimagrumab alongside the GLP-1-driven weight loss from semaglutide. This is a named clinical trial, elevating the evidence tier to RCT. No specific dosages for either agent are provided in the transcript.

Bimagrumab is being investigated in combination with GLP-1 agonists (e.g., semaglutide) and dual GLP-1/GIP agonists for synergistic fat loss while preserving or building muscle mass. The rationale is that GLP-1/GIP agonists drive caloric deficit and fat loss while bimagrumab counteracts the muscle-wasting side effect common to aggressive weight loss. No specific dosage protocols or frequencies are mentioned in the transcript.

Bimagrumab (BYM338) is currently under clinical investigation for the indication of muscle wasting that occurs during weight loss interventions. It is also being studied for its potential to actively promote muscle growth. The drug does not yet have a brand name, indicating it has not received regulatory approval. No specific dosage or trial phase details are provided in the transcript.

Bimagrumab is a monoclonal antibody (BYM338) that binds to ActR2 receptors on the surface of muscle cells. By occupying these receptors, it competitively blocks activin A and myostatin from binding, thereby reducing SMAD2/3 signaling cascade activity. This reduction in inhibitory signaling allows muscle cells to maintain or promote growth. No dosage figures are mentioned in this segment.